-
1 month ago | 
jamanetwork.com | Michael Liu |Christopher Worsham |Fatima Cody Stanford
Key PointsQuestion How do mortality rates differ by sex, race, and ethnicity among physicians and other health care workers in the US? Findings In this population-based cross-sectional study of 3 606 791 US workers aged 25 to 74 years, age-adjusted and sex-adjusted mortality rates per 100 000 were lower for most health care workers compared with non–health care workers.
-
Jul 9, 2024 | 
ajmc.com | Sammer Marzouk |Lucy Tu |Fatima Cody Stanford
Am J Manag Care. 2024;30(7):305-307_____Takeaway PointsIn 2024, physicians face significant financial challenges due to declining Medicare reimbursement rates and high student loan interest rates, which will impact health care delivery and access. Lower Medicare payments and high student loan debts are causing financial difficulties for doctors, potentially affecting their service quality and career choices.
-
Jun 17, 2024 | 
jamanetwork.com | Aditya Narayan |Ank Agarwal |Fatima Cody Stanford
Challenges With Relying on Body Fat and Weight Values for Obesity—Reply In Reply We express our gratitude to Kahn and Xiao for their thoughtful engagement with our Viewpoint on including fat loss measurements alongside weight as primary outcomes in clinical trials for anti-obesity medications.1 We happily maintain an ongoing dialogue with the medical community regarding the challenges and evolving methodologies in obesity treatment.
-
Jun 17, 2024 | 
jamanetwork.com | Lu Xiao |Ank Agarwal |Aditya Narayan |Fatima Cody Stanford
Challenges With Relying on Body Fat and Weight Values for Obesity Body Composition in Anti-Obesity Medication Trials Ank A. Agarwal, BA; Aditya Narayan, BS; Fatima Cody Stanford, MD, MPH, MPA, MBA Challenges With Relying on Body Fat and Weight Values for Obesity—Reply Aditya Narayan, BS; Ank A.
-
Feb 19, 2024 | 
jamanetwork.com | Ank Agarwal |Aditya Narayan |Fatima Cody Stanford
Body Composition in Anti-Obesity Medication Trials—Beyond Scales Obesity is the world’s most prevalent chronic disease and has increasingly been recognized as a global public health challenge. It has alarming health effects and burdens health care systems globally. From 2013 to 2016, approximately half of US adults undertook weight loss initiatives, reflecting widespread concerns about weight and efforts toward healthier living.
-
Feb 16, 2024 | 
nature.com | Fatima Cody Stanford
Correction to: Nature Reviews Gastroenterology & Hepatology https://doi.org/10.1038/s41575-023-00887-9, published online 13 December 2023.
-
Feb 7, 2024 | 
healio.com | Richard Smith |Fatima Cody Stanford
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eli Lilly and Co. released an open letter stating its tirzepatide products should not be used for cosmetic weight loss and warning the public about the circulation of compounded and counterfeit tirzepatide.
-
Feb 1, 2024 | 
healio.com | Andrew Rhoades |Carol L. DiBerardino |Fatima Cody Stanford
You've successfully added Primary Care: Obesity to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Overall, 56.2% patients who took semaglutide maintained their weight 1 year after discontinuing its use.
-
Jan 5, 2024 | 
healio.com | Emma Bascom |Carol L. DiBerardino |Fatima Cody Stanford
Fatima Cody Stanford, MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS I am unsurprised that the FDA has chosen to investigate the safety of GLP-1 single and dual agonist medications. These medications gained tremendous popularity in 2023, but unfortunately, they were often used in unsafe manners for various reasons. For example, many medications are being compounded due to high costs and lack of availability. Yet, these medications have never been studied. We don’t know if they are safe.
-
Jan 3, 2024 | 
nature.com | Fatima Cody Stanford
GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities. Metabolic and bariatric surgery is the most effective way to manage severe obesity with a body mass index (BMI) of ≥35 kg/m2.
